Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
Nery FC, Kaliszczak M, Suttle B, Jones L, Wu S, Xie J, Curiale G, Yesilalan E, Hirschhorn B, Wilkes D, Singh D, Bolin M, Nag S, Varrone A, Stenkrona P, Morén AF, Halldin C, Yachnin J, Arnold HM, Bullain S, Landen J, Gallagher D, Hering H.
Nery FC, et al.
J Prev Alzheimers Dis. 2025 Sep;12(8):100302. doi: 10.1016/j.tjpad.2025.100302. Epub 2025 Jul 21.
J Prev Alzheimers Dis. 2025.
PMID: 40695677
Free PMC article.
Clinical Trial.
BACKGROUND: Preclinical studies have demonstrated that inhibition of the O-linked beta-N-acetylglucosaminidase enzyme increases tau O-linked beta-N-acetylglucosaminylation and may attenuate tau pathology in Alzheimer's disease. OBJECTIVES: To examine the safety, tol …
BACKGROUND: Preclinical studies have demonstrated that inhibition of the O-linked beta-N-acetylglucosaminidase enzyme increases tau …